Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS

Affiliations

• ¹ From the Department of Neuroscience (G.N.), Ospedale Policlinico San Martino-IRCCS, Genoa; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI) (F.I., E.S., N.K.d.R.), University of Genoa; Department of Health Sciences (DISSAL) (M.M.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (M.M., G.P., M.I., A.U.), Genoa; Autoimmunity Laboratory Department of Internal Medicine (DiMI) (G.P.), University of Genoa; and Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI) and Center of Excellence for Biomedical Research (CEBR) (M.I., A.U.), University of Genoa, Italy. giovanninovi@gmail.com.
• ² From the Department of Neuroscience (G.N.), Ospedale Policlinico San Martino-IRCCS, Genoa; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI) (F.I., E.S., N.K.d.R.), University of Genoa; Department of Health Sciences (DISSAL) (M.M.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (M.M., G.P., M.I., A.U.), Genoa; Autoimmunity Laboratory Department of Internal Medicine (DiMI) (G.P.), University of Genoa; and Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI) and Center of Excellence for Biomedical Research (CEBR) (M.I., A.U.), University of Genoa, Italy.